Vistim Labs is a MedTech company pioneering accessible neurodiagnostic solutions for neurodegenerative diseases.
Their flagship platform, Ceregram, delivers precise, objective insights into brain function by using EEG-based visual processing and AI to help clinicians objectively monitor brain function, e.g. in Alzheimer’s Alzheimer’s and related dementias. Ceregram also tracks physiological and functional changes over time, offering insights comparable to PET or CSF biomarkers.
Designed for routine, office-based use, Ceregram enables fast, non-invasive assessments directly in neurology practices and memory clinics.
What Makes It Different
Unlike traditional cognitive testing or expensive imaging workflows, Ceregram delivers real-time physiological insights into how the brain processes information.
The platform supports:
- Early detection and monitoring of cognitive decline in Alzheimer’s and related dementias
- Therapy response monitoring
- Longitudinal disease tracking
- Personalized treatment decisions
Current Status
Ceregram is commercially available in private neurology practices across the United States and continues to expand through clinical partnerships and validation studies.
NMV Collaboration
Neuromotion Ventures supports Vistim Labs with strategic neurotechnology expertise, commercialization guidance, and access to scientific and commercial networks.